CompletedPhase 2NCT01392079
Subcutaneous Alemtuzumab Combined With Oral Dexamethasone, Followed by Alemtuzumab Maintenance or Allo-SCT in CLL With 17p- or Refractory to Fludarabine
Studying B-cell chronic lymphocytic leukemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University of Ulm
- Principal Investigator
- Stephan Stilgenbauer, Prof Dr medUniversity of Ulm
- Intervention
- Alemtuzumab(drug)
- Enrollment
- 135 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2008 – 2016
Study locations (30)
- Hanuschkrankenhaus Wien, Vienna, Austria
- University Hospital, Vienna, Austria
- Centre Hospitalier de la Côte Basque, Bayonne, France
- Hopital Avicenne, Bobigny, France
- CHU Estaing, Clermont-Ferrand, France
- Hôpital Henri Mondor, Creteil -APHP, Créteil, France
- CHU de Grenoble, Grenoble, France
- CHU Claude Huriez, Lille, France
- Hôpital Edouard Herriot Lyon, Lyon, France
- CHU de Nancy, Nancy, France
- CHU Nantes, Nantes, France
- Hôpital Pitié Salpêtrière Paris-APHP, Paris, France
- Hôpital Saint-Louis Paris -APHP, Paris, France
- Centre Hospitalier Marechal Joffre Hôpital Saint-Jean Perpignan, Perpignan, France
- CHU de Poitiers, Poitiers, France
- +15 more locations on ClinicalTrials.gov
Collaborators
Technical University of Munich · WiSP Wissenschaftlicher Service Pharma GmbH · German CLL Study Group
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01392079 on ClinicalTrials.govOther trials for B-cell chronic lymphocytic leukemia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07194980Nemtabrutinib and Lisocabtagene Maraleucel for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaFred Hutchinson Cancer Center
- RECRUITINGEARLY PHASE1NCT07428707Immune Profiling of CLL/SLL Treated With First-Line PirtobrutinibNational Heart, Lung, and Blood Institute (NHLBI)
- RECRUITINGPHASE4NCT07218341A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaEli Lilly and Company
- RECRUITINGPHASE1NCT06859008Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin LymphomaCity of Hope Medical Center
- RECRUITINGPHASE2NCT07271667A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell MalignanciesCuris, Inc.
- RECRUITINGPHASE2NCT07014917Intermittent Versus Continuous Venetoclax With Acalabrutinib for CLL/SLLZulfa Omer
- RECRUITINGPHASE2NCT06958705Venetoclax as Consolidation in CLL Patients Treated With BTK Inhibitor MonotherapyThe First Affiliated Hospital with Nanjing Medical University
- RECRUITINGPHASE1, PHASE2NCT07052695Mosunetuzumab for CLL MRD ClearanceInhye Ahn